Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Using Viral Therapy To Reverse Liver Disease

XTALKS VITALS NEWS

Liver Failure

The viral therapy works to reverse the continuous scarring of the liver, known as liver fibrosis, which eventually results in organ failure.

Share this!

June 6, 2016 | by Sarah Massey, M.Sc.

Researchers have used a modified virus to help repair damaged hepatocytes in mice with liver disease. If it proves to be similarly effective in humans, the technique could be a much-needed treatment option for thousands of patients diagnosed with liver disease.

In the US alone, over 35,000 people die of liver disease every year. The viral therapy works to reverse the continuous scarring of the liver, known as liver fibrosis, which eventually results in organ failure.

Liver disease is often caused by exposure of hepatocytes to alcohol, or stress caused by disease. As healthy hepatocytes are damaged and die, myofibroblasts take their place by generating collagen-based scar tissue. Once the liver reaches a critical number of hepatocytes, it is unable to perform its functions and goes into liver failure.

Dr. Holger Willenbring and his colleagues at the University of California, San Francisco, developed a new technique whereby myofibroblasts could be transformed into hepatocytes using viral therapy. The researchers used a modified adeno-associated virus to deliver liver transcription factors into the myofibroblast cells of liver-damaged mice. After infection with the genetically modified virus, the transcription factor genes are integrated into the host cell’s genome, inducing the cells to transform into hepatocytes.



The researchers found that the viral therapy reduced the collagen content of the mice livers by about one third, as well as increased the number of healthy liver cells. “We think the combination of making more hepatocytes and reducing collagen is the most promising approach to treating liver fibrosis,” said Willenbring. Tweet: Making hepatocytes and reducing collagen to treat #liverfibrosis http://ctt.ec/R2d9V+

According to Vanessa Hebditch, director of communications and policy at the British Liver Trust, the research could have exciting implications for the future treatment of liver disease. “The vector used in these studies is one that has already been used in the treatment of other human diseases so this is a promising approach.”

Adeno-associated viral therapy has been tested in multiple clinical trials for diseases like cystic fibrosis, hemophilia and retinal eye conditions. Willenbring expects that it will be five years or more before the viral therapy can be tested in human liver disease patients.


Keywords: Liver Disease, Viral Therapy, Clinical Trial


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Early Alzheimer’s Patients May See Benefit from Anti-Epilepsy Drug

June 27, 2017 - While the processes behind Alzheimer’s disease development aren’t fully understood, recent research has suggested that some cognitive decline could be caused by seizure-like activity in the brains of patients.

Featured In: Clinical Trials News


First Human Colon Organoids Grown in Lab

June 26, 2017 - Using human pluripotent stem cells, researchers at Cincinnati Children's Hospital Medical Center have developed colon-like organoids that can be transplanted into mice.

Featured In: Life Science News


Could Genetic Markers Help Identify Patients at Risk of Opioid Overdose?

June 26, 2017 - Researchers at Erasmus University Medical Center in the Netherlands have identified 10 genes which may help healthcare providers predict which patients could respond poorly to opioid medications.

Featured In: Drug Safety News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Drug Development During the Last Week

REGISTER FOR THESE WEBINARS

Serialized? Yes. But are Products Still Being Diverted?


Quantitative Protein Profiling in FFPE to Characterize Toxicities Associated with Immune Checkpoint Inhibitors


Are You Choosing the Right Model? A Guide to Selecting Your Next Immuno-Oncology Model


Imaging-based Subtypes of Pancreatic Cancer


Copyright © 2016-2017 Honeycomb Worldwide Inc.